These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9410836)

  • 1. [Screening in activated protein C resistance].
    Bergmann F
    Internist (Berl); 1997 Sep; 38(9):864. PubMed ID: 9410836
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening.
    Fábregues F; Tàssies D; Reverter JC; Carmona F; Ordinas A; Balasch J
    Fertil Steril; 2004 Apr; 81(4):989-95. PubMed ID: 15066453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thrombophilia--often a case of genetic susceptibility. Thrombosis ABC, 6: Protein C deficiency].
    Stiefelhagen P
    MMW Fortschr Med; 1999 Nov; 141(45):52. PubMed ID: 10795169
    [No Abstract]   [Full Text] [Related]  

  • 4. Polymorphisms in the endothelial protein C receptor gene and thrombophilia.
    Medina P; Navarro S; Estellés A; España F
    Thromb Haemost; 2007 Sep; 98(3):564-9. PubMed ID: 17849044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation screening for thrombophilia: two cases with factor V Cambridge without activated protein C resistance.
    ten Cate AJ; van de Hoek YT; Reitsma PH; ten Cate H; Smits P
    Thromb Haemost; 2002 May; 87(5):919-20. PubMed ID: 12038799
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular genetics of thrombophilia: factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state.
    Dahlbäck B
    J Lab Clin Med; 1995 May; 125(5):566-71. PubMed ID: 7738422
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
    Favaloro EJ; Mirochnik O; McDonald D
    Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor V Leiden: an overview.
    Shaw DM
    Clin Lab Sci; 2006; 19(4):218-21. PubMed ID: 17181126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes in hemostasis system in patients with hereditary thrombophilia caused by mutation of blood coagulation factor V ( factor V Leiden)].
    Papaian LP; Kobilianskaia VA; Sheĭdina AM; Baranovskaia SS; Sirotkina OV; Kargin VD; Saltykova NB; Beliazo OE; Golovina OG; Papaian KA; Tarkovskaia LR
    Ter Arkh; 2001; 73(7):47-51. PubMed ID: 11523408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives--a short review.
    Jespersen J
    Eur J Contracept Reprod Health Care; 1996; 1(1):3-11. PubMed ID: 9678132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to activated protein C: a major cause of inherited thrombophilia.
    Jensen R; Ens GE
    Clin Lab Sci; 1997; 10(4):219-22. PubMed ID: 10169621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased resistance to activated protein C and factor V Leiden in recurrent abortions. Review of other hypercoagulability factors.
    Hatzis T; Cardamakis E; Drivalas E; Makatsoris K; Bevan D; Pantos C; Malliopoulou V; Tsagaris N; Kreatsa O; Antoniadi T; Petersen MB; Karageorgiou H; Mantouvalos H
    Eur J Contracept Reprod Health Care; 1999 Sep; 4(3):135-44. PubMed ID: 10574639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Activated protein C resistance syndrome].
    Souto JC; Fontcuberta J
    Sangre (Barc); 1997 Dec; 42(6):453-66. PubMed ID: 9490910
    [No Abstract]   [Full Text] [Related]  

  • 14. [Constitutional thrombophilias: indications of the biological profile and therapeutic consequences].
    Trillot N; Rugeri L; Jude B
    Therapie; 1999; 54(4):413-8. PubMed ID: 10667107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Factor V Leiden and thrombophilia].
    Mahassen P; Dicato M
    Bull Soc Sci Med Grand Duche Luxemb; 1997; 134(2):17-22. PubMed ID: 9534269
    [No Abstract]   [Full Text] [Related]  

  • 16. Resistance to activated protein C as a risk factor of stroke in a thalassemic patient.
    Giordano P; Sabato V; Schettini F; De Mattia D; Iolascon A
    Haematologica; 1997; 82(6):698-700. PubMed ID: 9499670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Thai patient with the mutation of Arg306 of FV gene identical to the Hong Kong but not to the Cambridge type.
    Hiyoshi M; Hashimoto S; Tagawa S; Arnutti P; Prayoonwiwat W; Tatsumi N
    Thromb Haemost; 1999 Nov; 82(5):1553-4. PubMed ID: 10595653
    [No Abstract]   [Full Text] [Related]  

  • 18. The endothelial cell protein C receptor: a candidate genetic risk factor for thrombosis.
    Simmonds RE; Lane DA
    Thromb Haemost; 2001 Oct; 86(4):939-41. PubMed ID: 11686348
    [No Abstract]   [Full Text] [Related]  

  • 19. Inherited thrombophilia: an update.
    Franchini M; Veneri D
    Clin Lab; 2005; 51(7-8):357-65. PubMed ID: 16122145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inherited homozygous resistance to activated protein C.
    Villa P; Aznar J; Jorquera J; Mira Y; Vayá A; Fernández MA
    Thromb Haemost; 1995 Aug; 74(2):794-5. PubMed ID: 8585025
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.